Changing the route of immunotherapy administration: An 18-year survey in pediatric patients with allergic rhinitis and asthma

Allergy and Asthma Proceedings

Volumn 34, Issue 6, 2013, Pages 523-526

  Pajno, Giovanni B ^a   Caminiti, Lucia ^a   Passalacqua, Giovanni ^b  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; BETAMETHASONE; CETIRIZINE;

ADOLESCENT; ADULT; ALLERGIC RHINITIS; ARTICLE; ASTHMA; CHILD; FEMALE; GRASS; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PARIETARIA; PARIETARIA JUDAICA; PRESCHOOL CHILD; RETROSPECTIVE STUDY; SCHOOL CHILD; SUBCUTANEOUS IMMUNOTHERAPY; SUBLINGUAL IMMUNOTHERAPY;

ADMINISTRATION, SUBLINGUAL; ADOLESCENT; ASTHMA; CHILD; CHILD, PRESCHOOL; DESENSITIZATION, IMMUNOLOGIC; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MEDICATION ADHERENCE; PATIENT PREFERENCE; RETROSPECTIVE STUDIES; RHINITIS, ALLERGIC, PERENNIAL; RHINITIS, ALLERGIC, SEASONAL;

EID: 84888405214     PISSN: 10885412     EISSN: 15396304     Source Type: Journal    
DOI: 10.2500/aap.2013.34.3696     Document Type: Article

References (24)

1. Bousquet J, Van Cauwenberge P, and Khaltaev N. Aria Workshop Group; World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 108(suppl 5):S147-S334, 2001.
2. Global Initiative on Asthma. Available online at www.ginasthma.org; accessed July 2012.
3. Soyer OU, Akdis M, and Akdis CA. Mechanisms of subcutaneous allergen immunotherapy. Immunol Allergy Clin North Am 31:175-190, 2011.
4. Jutel M, and Akdis CA. Immunological mechanisms of allergenspecific immunotherapy. Allergy 66:725-732, 2011.
5. Passalacqua G. Specific immunotherapy: Beyond clinical scores. Ann Allergy Asthma Immunol 107:401-406, 2011.
6. Bousquet J, Lockey R, and Malling HJ. World Health Organization Position Paper. Allergen immunotherapy: Therapeutic vaccines for allergic diseases. Allergy 53(suppl 44):1-42, 1998.
7. Frieri M. New frontiers in immunotherapy. Allergy Asthma Proc 20:281-288, 1999.
8. Malling H-J, Abreu-Nogueira J, Alvarez-Cuesta E, et al. EAACI position paper on local immunotherapy. Allergy 53:933-944, 1998.
9. Canonica GW, Bousquet J, Casale T, et al. Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009. Allergy 64(suppl 91):1-59, 2009.
10. Khinchi S, Poulsen LK, Carat F, et al. Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: A randomized, placebo-controlled, double-blind double-dummy study. Allergy 59:45-53, 2004.
11. Eifan AO, Akkoc T, Yildiz A, et al. Clinical efficacy and immunological mechanisms of sublingual and subcutaneous immunotherapy in asthmatic/rhinitis children sensitized to house dust mite: An open randomized controlled trial. Clin Exp Allergy 40:922-932, 2010.
12. Brozek JL, Baena-Cagnani CE, Bonini S, et al. Methodology for development of the Allergic Rhinitis and Its Impact on Asthma guideline 2008 update. Allergy 63:38-46, 2008.
13. Reisacher WR, and Visaya JM. Patient adherence to allergy immunotherapy. Curr Opin Otolaryngol Head Neck Surg 21:256-262, 2013.
14. Scurati S, Frati F, Passalacqua G, et al. Adherence issues related to sublingual immunotherapy as perceived by allergists. Patient Prefer Adherence 4:141-145, 2010.
15. Bukstein D, Luskin AT, and Farrar JR. The reality of adherence to rhinitis treatment: Identifying and overcoming the barriers. Allergy Asthma Proc 32:265-271, 2011.
16. Vita D, Caminiti L, Ruggeri P, and Pajno GB. Sublingual immunotherapy: Adherence based on timing and monitoring control visits. Allergy 65:668-669, 2010.
17. Di Bona D, Plaia A, Leto-Barone MS, et al. Efficacy of subcutaneous and sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: A meta-analysis-based comparison. J Allergy Clin Immunol 130:1097-1107, 2012.
18. Epstein TG, Liss GM, Murphy-Beredents K, and Bernstein DI. Immediate and delayed-onset systemic reactions after subcutaneous immunotherapy injections: ACAAI/AAAAI surveillance study of subcutaneous immunotherapy: Year 2. Ann Allergy Asthma Immunol 107:426-431, 2011.
19. Cox L, Calderon M, and Pfaar O. Subcutaneous allergen immunotherapy for allergic disease: Examining efficacy, safety, and cost-effectiveness of current and novel formulations. Immunotherapy 4:601- 616, 2012.
20. Burks AW, Calderon MA, Casale T, et al. Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Imunology/PRACTALL consensus report. J Allergy Clin Immunol 131:1288-1296, 2013.
21. Bernstein DI, Epstein T, Murphy-Berendts K, and Liss GM. Surveillance of systemic reactions to subcutaneous immunotherapy injections: Year 1 outcomes of the ACAAI and AAAAI collaborative study. Ann Allergy Asthma Immunol 104:530-535, 2010.
22. Passalacqua G, Baena Cagnani CE, Canonica GW, et al. Grading the local side effects of sublingual immunotherapy: Speaking the same language. J Allergy Clin Immunol 132:93-98, 2013.
23. Cox L, Compalati E, Kundig T, and Larche M. New directions in immunotherapy. Curr Allergy Asthma Rep 13:178-195, 2013.
24. Nelson HS. Is sublingual immunotherapy ready for use in the United States? JAMA 309:1297-1298, 2013.